Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.
Jagadeswara Rao EarlaGeorge J HuttonJames Douglas ThorntonHua ChenMichael L JohnsonRajender R AparasuPublished in: Patient preference and adherence (2020)
Oral DMA fingolimod was associated with better adherence than injectable DMAs across group-based trajectories. Further research is warranted to evaluate the adherence trajectories with newer oral DMAs introduced in the last decade for MS.